Cogent Biosciences 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim, and the first presenting company here is Cogent Biosciences. With me, I have Andrew Robbins, CEO. Andrew, welcome. Thanks for joining us.
Thanks, Mike, for inviting us.
Glad to be here. Andrew, we were just talking, Cogent is obviously weeks, if not days away from its first FDA decision, with two more to follow.
How are you preparing to become a commercial company, and what does a successful first year look like for you?
Yeah. We're, as you say, imminently awaiting, hopefully, an approval from the FDA. For folks that aren't as familiar, we've been developing a drug called bezuclastinib, which is a selective potent KIT inhibitor for three different patient populations, within systemic mastocytosis, both the non-advanced and advanced form of the disease, and then in gastrointestinal stromal tumors for patients who have developed resistance on imatinib therapy. Each of those pivotal studies read out during 2025, and most of 2026 has been a process of filing the NDAs and working with the FDA, hopefully for some very near-term approvals. In addition to all the regulatory and development work that we've been doing, of course, we've been planning and onboarding a commercial team to be ready to launch the product ourselves here in the U.S., and we're very excited and waiting anxiously for the word to say go.
We have our entire home office, commercial team, and medical teams in place long ago. In Q3, we onboarded all of our field professionals who have territories around the country, and they have been working very hard to develop relationships, doing introductions, telling people who Cogent is, and getting ready for the day when they are ready to sell the product. Hopefully that is not too much longer.
Again, the first PDUFA date for the GIST opportunity is November 30. I guess, what is your confidence at this time in an on-time approval as we get close to the date?
I never like to speak in definites about things in the future, but we feel very confident, as confident as I think we can be, that it is literally a matter of days until we get the green light from the FDA. The team is ready. I know the investigators, the patients are certainly ready to get access to an important new drug in the treatment of gastrointestinal stromal tumors based on the data from the phase III PEAK trial. I think everybody is ready. Now it is just in the hands of the government to let us know when the right day is.
There has been some investor focus on the label specifics around the GIST label, liver enzyme warnings, or potentially monitoring around bezuclastinib. What is your view on how the label might impact the opportunity potentially?
Yeah. Also, the label, as folks know, is usually the very, very last thing, literally in the days leading up to an approval. Not being able to give you a definitive answer. What I can tell you about gastrointestinal stromal tumor patients is that for the last 20 years, the standard of care has been a drug called sunitinib, and GIST physicians are extremely familiar with a drug that carries its own language around transaminase monitoring. The protocol for treating GIST patients today, and last year, and 20 years ago, has always been to monitor for transaminases. We don't see any language that would suggest you need to monitor for transaminases as anything different than what these physicians, both here in the U.S. and around the world, are used to doing already.
We've said for years, since we characterized the profile of this drug, that it's probably going to be a good idea to monitor transaminases in these patients. What's important in the clinical studies, and this persists till today, is we don't have any adverse events reported clinically as hepatic adverse events. All of our adverse events are lab abnormalities. All of our patients across the studies, APEX, SUMMIT, and PEAK, either had no problems at all, or the ones that had higher grade transaminases had either dose reductions or, in very, very rare cases, discontinuation of drug with a complete return to baseline.
We think that this drug has an amazing profile from an activity perspective, and we acknowledge that it's a good idea to monitor patients in a metastatic cancer population, and specifically in second-line GIST, we don't see that as being any different than what's been done for the past 20 years.
Yeah. When we speak with sarcoma specialists and oncologists in general, they're obviously very familiar, and it's very common for many cancer drugs to monitor for enzyme elevations. But given that SUTENT has a black box for that, do you expect it to carry over into the bezuclastinib label?
It's a great question, unfortunately, there's not a simple answer to that. When you look at the history of products approved for the first time in combination with another product, there are many cases where you see some of the warnings and precautions or safety language from the on-market product carry over to the new product. There are other cases where you don't. I think there's not a hard and fast rule about how that's going to be handled. In our case, we have bezuclastinib being developed as a monotherapy at lower doses in a different disease, where you also see the benefit of monitoring transaminases. I think we feel pretty confident, we acknowledge it's the right thing to do for the clinical care of patients to check transaminases.
But what's important, again, is that in no patient has it led to any serious clinical outcome.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
